Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA) from its SEC filings: 2025 revenue $67.7 million (+17% vs the year before), net margin -610%, free cash flow -$395.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Revenue (2025) | $67.7 million |
| Revenue growth | +17% |
| Net income | -$412.7 million |
| Net margin | -609.9% |
| Free cash flow | -$395.9 million |
| Diluted EPS | $-3.81 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -46% |
| Cash | $106.1 million |
| Share count, 1 year | +30% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.